Rigontec, a private German biopharma company developing RNA-based immunotherapies, has appointed Donald deBethizy Chairman. He replaces Gunther Hartmann, Rigontec’s co-founder and outgoing Chairman.
DeBethizy has more than 30 years of R&D experience, as well as financial and operational management in the biotechnology industry. He is currently President of White City Consulting in Denmark and serves on the supervisory boards of arGEN-X, Newron Pharmaceuticals, Serendex Pharmaceuticals, and Noxxon Pharma.
DeBethizy previously led Santaris Pharma until the company’s acquisition by Roche, and was Executive Chairman of Contera Pharma until it was sold to Bukwang Pharma in 2014.